The estimated Net Worth of Paul J Sekhri is at least $9.76 Million dollars as of 1 September 2024. Mr. Sekhri owns over 329 units of Veeva Systems Inc stock worth over $3,511,424 and over the last 10 years he sold VEEV stock worth over $5,988,837. In addition, he makes $254,867 as Independent Director at Veeva Systems Inc.
Paul has made over 53 trades of the Veeva Systems Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 329 units of VEEV stock worth $73,663 on 1 September 2024.
The largest trade he's ever made was exercising 20,000 units of Veeva Systems Inc stock on 17 June 2021 worth over $542,800. On average, Paul trades about 2,062 units every 40 days since 2014. As of 1 September 2024 he still owns at least 15,683 units of Veeva Systems Inc stock.
You can see the complete history of Mr. Sekhri stock trades at the bottom of the page.
Paul Jai Sekhri serves as Independent Director of the Company. Mr. Sekhri was appointed President and CEO of eGenesis, Inc., a biotechnology company focused on transplantation. Prior to joining eGenesis, Mr. Sekhri served as President and CEO of Lycera Corp., a biopharmaceutical company, from February 2015 to January 2019. From February 2016 to May 2017, Mr. Sekhri was Operating Partner at Highline Therapeutics, a biotech incubator launched by Versant Ventures. Mr. Sekhri was Senior Vice President, Integrated Care at Sanofi S.A., a multinational pharmaceutical company headquartered in France, from April 2014 to January 2015. From May 2013 to March 2014, Mr. Sekhri was Group Executive Vice President, Global Business Development and Chief Strategy Officer at Teva Pharmaceutical Industries, Ltd., a global pharmaceuticals company focusing on the manufacture of generic and proprietary pharmaceutical products headquartered in Israel. From January 2009 to May 2013, Mr. Sekhri was Operating Partner and Head, Biotech Ops Group at TPG Biotech, the life sciences venture arm of the global private investment firm TPG Capital, where he was responsible for a portfolio of more than 50 life sciences companies. From December 2004 to January 2009, Mr. Sekhri was President and CEO of Cerimon Pharmaceuticals, Inc., a pharmaceutical company focusing on auto-immune diseases and pain management. Mr. Sekhri completed post-graduate studies in clinical anatomy and neuroscience at the University of Maryland, School of Medicine and received a Bachelor of Science degree in Zoology from the University of Maryland.
As the Independent Director of Veeva Systems Inc, the total compensation of Paul Sekhri at Veeva Systems Inc is $254,867. There are 15 executives at Veeva Systems Inc getting paid more, with Thomas Schwenger having the highest compensation of $8,090,590.
Paul Sekhri is 62, he's been the Independent Director of Veeva Systems Inc since 2014. There are 2 older and 19 younger executives at Veeva Systems Inc. The oldest executive at Veeva Systems Inc is Timothy Barabe, 67, who is the Independent Director.
Paul's mailing address filed with the SEC is C/O VEEVA SYSTEMS INC., 4280 HACIENDA DRIVE, PLEASANTON, CA, 94588.
Over the last 11 years, insiders at Veeva Systems Inc have traded over $2,373,995,980 worth of Veeva Systems Inc stock. The most active insiders traders include Gordon Ritter, Capital Partners Ii Lpemerg... und Kevin Spain. On average, Veeva Systems Inc executives and independent directors trade stock every 3 days with the average trade being worth of $12,654,156. The most recent stock trade was executed by Timothy S Cabral on 1 September 2024, trading 315 units of VEEV stock currently worth $70,529.
veeva systems inc. is a leader in cloud-based software for the global life sciences industry. committed to innovation, product excellence, and customer success, veeva has more than 300 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. veeva is headquartered in the san francisco bay area, with offices in europe, asia, and latin america. for more information, visit www.veeva.com.
Veeva Systems Inc executives and other stock owners filed with the SEC include: